Breakout Setups
MIRM appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
MIRUM PHARMACEUTICALS INC (MIRM) Stock Price & Overview
NASDAQ:MIRM • US6047491013
Current stock price
92.48 USD
+0.99 (+1.08%)
At close:
92.48 USD
0 (0%)
After Hours:
The current stock price of MIRM is 92.48 USD. Today MIRM is up by 1.08%. In the past month the price increased by 4.57%. In the past year, price increased by 111.67%.
MIRM Key Statistics
52-Week Range40.001 - 109.28
Current MIRM stock price positioned within its 52-week range.
1-Month Range86.97 - 99.4069
Current MIRM stock price positioned within its 1-month range.
- Market Cap
- 5.58B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.47
- Dividend Yield
- N/A
MIRM Stock Performance
Today
+1.08%
1 Week
-3.37%
1 Month
+4.57%
3 Months
-10.41%
Longer-term
6 Months +27.30%
1 Year +111.67%
2 Years +268.30%
3 Years +244.43%
5 Years +373.29%
10 Years N/A
MIRM Stock Chart
MIRM Stock Screens
MIRM currently appears in the following ChartMill screener lists.
MIRM Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MIRM. When comparing the yearly performance of all stocks, MIRM is one of the better performing stocks in the market, outperforming 90.23% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
MIRM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to MIRM. The financial health of MIRM is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MIRM Earnings
On February 25, 2026 MIRM reported an EPS of -0.1 and a revenue of 148.93M. The company missed EPS expectations (-331.01% surprise) and beat revenue expectations (2.97% surprise).
Next Earnings DateApr 30, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported-$0.10
Revenue Reported148.932M
EPS Surprise -331.01%
Revenue Surprise 2.97%
MIRM Forecast & Estimates
17 analysts have analysed MIRM and the average price target is 127.87 USD. This implies a price increase of 38.27% is expected in the next year compared to the current price of 92.48.
For the next year, analysts expect an EPS growth of -304.14% and a revenue growth 25.28% for MIRM
Analysts
Analysts85.88
Price Target127.87 (38.27%)
EPS Next Y-304.14%
Revenue Next Year25.28%
MIRM Groups
Sector & Classification
MIRM Financial Highlights
Over the last trailing twelve months MIRM reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS increased by 74.59% compared to the year before.
Income Statements
Revenue(TTM)521.31M
Net Income(TTM)-23.36M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.77% | ||
| ROE | -7.42% | ||
| Debt/Equity | 0.98 |
Chartmill High Growth Momentum
EPS Q2Q%79.59%
Sales Q2Q%49.81%
EPS 1Y (TTM)74.59%
Revenue 1Y (TTM)54.74%
MIRM Ownership
Ownership
Inst Owners90.78%
Shares60.34M
Float51.14M
Ins Owners1.39%
Short Float %15.74%
Short Ratio9.42
MIRM Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.31 | 351.47B | ||
| AMGN | AMGEN INC | 14.9 | 185.95B | ||
| GILD | GILEAD SCIENCES INC | 14.45 | 161.855B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.87 | 109.449B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.88 | 79.456B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.2 | 40.768B | ||
| INSM | INSMED INC | N/A | 29.176B | ||
| NTRA | NATERA INC | N/A | 28.878B | ||
| BIIB | BIOGEN INC | 11.21 | 27.06B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.812B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.4 | 24.859B | ||
| MRNA | MODERNA INC | N/A | 20.119B | ||
| INCY | INCYTE CORP | 12.37 | 18.836B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MIRM
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
Company Info
IPO: 2019-07-18
MIRUM PHARMACEUTICALS INC
989 East Hillsdale Boulevard, Suite 300
Foster City CALIFORNIA 94404 US
CEO: Christopher Peetz
Employees: 369
Phone: 13023368212
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What does MIRM do?
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
Can you provide the latest stock price for MIRUM PHARMACEUTICALS INC?
The current stock price of MIRM is 92.48 USD. The price increased by 1.08% in the last trading session.
Does MIRM stock pay dividends?
MIRM does not pay a dividend.
What is the ChartMill rating of MIRUM PHARMACEUTICALS INC stock?
MIRM has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is MIRM stock listed?
MIRM stock is listed on the Nasdaq exchange.
What do analysts say about MIRUM PHARMACEUTICALS INC (MIRM) stock?
17 analysts have analysed MIRM and the average price target is 127.87 USD. This implies a price increase of 38.27% is expected in the next year compared to the current price of 92.48.
What is the expected growth for MIRM stock?
The Revenue of MIRUM PHARMACEUTICALS INC (MIRM) is expected to grow by 25.28% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.